Comparative study of high-dose Xuezhikang and low-dose Xuezhikang plus ezetimibe on pro- and anti-inflammatory markers

References

• Li J-J. Inflammation: an important mechanism for different clinical entities of coronary artery disease. Chin. Med. J. 118, 1817–1826 (2005).
   Google Scholar
• Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670–1681 (2010).
   Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature 420, 868–874 (2002).
   Google Scholar
• Rosenson RS, Tangney CC. Anti-atherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 279, 1643–1650 (1998).
   Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495–1504 (2004).
   Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360, 7–22 (2002).
   Google Scholar
• Stettergren M, Bohm F, Ryden L, Pernow J. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur. Heart J. 29, 1753–1760 (2008).
   Google Scholar
• Al-Shaer MH, Choueiri NE, Suleiman ES. The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemia. Lipids Health Dis. 3, 22–27 (2004).
   Google Scholar
• Liu P-Y, Liu Y-W, Lin L-J, Chen J-H, Liao JK. Evidence for statin pleiotropic in humans: differential effects of statins and ezetimibe on Rho-associated coiled-coil containing protein kinase activity, endothelial function and inflammation. Circulation 119, 131–138 (2009).
   Google Scholar
• Araujo DB, Bertolami MC, Ferreira WP et al. Pleiotropic effects with equivalent low-density lipoprotein cholesterol reduction: comparative study between simvastatin and simvastatin/ ezetimibe coadministration. J. Cardiovasc. Pharmacol. 55, 1–5 (2010).
   Google Scholar
• Dagli N, Yavuzkir M, Karaca I. The effects of high dose pravastatin and low dose pravasattin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation 30, 230–235 (2007).
   Google Scholar
• Kater AA, Batista MC, Ferreira RG. Synergistic effects of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects. Diabet. Metabol. Syndrome 2, 34–41 (2010).
   Google Scholar
• Lu Z-L, Kou W-R, Du B-M et al. Effects of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am. J. Cardiol. 101, 1689–1693 (2008). ▪▪ First randomized controlled trial demonstrating the beneficial impacts of Xuezhikang on cardiovascular events in a large cohort of Chinese patients with previous myocardial infarction.
   Google Scholar
• Li J-J, Lu Z-L, Kou W-R et al. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from China Coronary Secondary Prevention Study (CCSPS). J. Clin. Pharmacol. 49, 947–956 (2009).
   Google Scholar
• Li J-J, Hu S-S, Fang C-H et al. Effects of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina. Clin. Chim. Acta 352, 217–224 (2005).
   Google Scholar
• Li J-J, Wang Y, Nie S-P, Li Y-S, Huang Y, Hui R-T. Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improve exercise-induced ischemia and subjective feeling in patients with cardiac syndrome X. Int. J. Cardiol. 122, 82–84 (2007).
   Google Scholar
• Li J-J, Fang C-H. Effects of 4 weeks of atorvastatin administration on the anti-inflammatory cytokine interleukin-10 in patients with unstable angina. Clin. Chem. 51, 1735–1738 (2005). ▪ The impact of statins on plasma IL-10 levels in patients with coronary artery disease was first reported in this study.
   Google Scholar
• Zhao S-P, Liu L, Cheng Y-C et al. Xuezhikang, an extract of cholestin, protects endothelial function through anti-inflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation 110, 915–920 (2004).
   Google Scholar
• Becker, DJ, Gordon RY, Halbert S C et al. Red yeast rice for dyslipidemia in statin-intolerant patients. Ann. Intern. Med. 150, 830–839 (2009). ▪ First study assessing the utility of red yeast rice in statin-intolerant patients.
   Google Scholar
• Halbert, SC, French B, Gordon R Y et al. Tolerability of red yeast rice (2400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am. J. Cardiol. 105, 198–204 (2010).
   Google Scholar
• Ridler PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195–2207 (2008).
   Google Scholar
• Sabat R, Grutz G, Warszawska K et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 21, 331–344 (2010).
   Google Scholar
• Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the anti-inflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 104, 746–749 (2001). ▪ First study demonstrating that patients with unstable angina had lower IL-10 levels.
   Google Scholar
• Li J-J, Fang C-H, Li Y-S et al. Effects of simvastatin on anti-inflammatory cytokine IL-10 in patients with unstable angina within two weeks. Heart 92, 529–530 (2006).
   Google Scholar